| Title |
Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia
|
|---|---|
| Published in |
Cochrane database of systematic reviews, September 2012
|
| DOI | 10.1002/14651858.cd009045.pub2 |
| Pubmed ID | |
| Authors |
Liat Vidal, Anat Gafter‐Gvili, Ronit Gurion, Pia Raanani, Martin Dreyling, Ofer Shpilberg |
| Abstract |
Indolent B cell lymphoid malignancies include follicular lymphoma, small lymphocytic lymphoma, mantle cell lymphoma, lymphoplasmacytic lymphoma and marginal zone lymphomas. Chronic lymphocytic leukaemia (CLL) is a lymphoid malignancy similar to small lymphocytic lymphoma (SLL) in its leukaemic phase.Indolent lymphoid malignancies including CLL are characterised by slow growth, a high initial response rate and a relapsing and progressive disease course. Advanced-stage indolent B cell lymphoid malignancies are often incurable. If symptoms or progressive disease occur, chemotherapy plus rituximab is indicated. No chemotherapy regimen has been shown to improve overall survival compared to a different regimen.Bendamustine is efficacious in the treatment of patients with indolent B cell lymphoid malignancies. A number of randomised controlled trials have examined the effect of bendamustine compared to other chemotherapy regimens in these patients. Improved disease control with no survival benefit is shown. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 117 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Switzerland | 1 | <1% |
| Unknown | 115 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 14 | 12% |
| Student > Bachelor | 13 | 11% |
| Other | 11 | 9% |
| Researcher | 11 | 9% |
| Student > Ph. D. Student | 11 | 9% |
| Other | 24 | 21% |
| Unknown | 33 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 54 | 46% |
| Nursing and Health Professions | 10 | 9% |
| Psychology | 4 | 3% |
| Economics, Econometrics and Finance | 3 | 3% |
| Agricultural and Biological Sciences | 2 | 2% |
| Other | 10 | 9% |
| Unknown | 34 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 January 2016.
All research outputs
#20,132,580
of 25,611,630 outputs
Outputs from Cochrane database of systematic reviews
#12,105
of 13,150 outputs
Outputs of similar age
#142,080
of 187,777 outputs
Outputs of similar age from Cochrane database of systematic reviews
#216
of 231 outputs
Altmetric has tracked 25,611,630 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 13,150 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.7. This one is in the 6th percentile – i.e., 6% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 187,777 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 231 others from the same source and published within six weeks on either side of this one. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.